We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · November 07, 2020

Renal Outcomes and All-Cause Death Associated With SGLT-2 Inhibitors

Diabetes, Obesity & Metabolism

 

Additional Info

Diabetes, Obesity & Metabolism
Renal Outcomes and All-Cause Death Associated With SGLT-2 Inhibitor Versus Other Glucose-Lowering Drugs (CVD-REAL 3 Korea)
Diabetes Obes Metab 2020 Oct 29;[EPub Ahead of Print], ES Koh, K Han, YS Nam, ET Wittbrodt, P Fenici, M Kosiborod, HJL Heerspink, SJ Yoo, HS Kwon

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading